SG Americas Securities LLC Lowers Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

SG Americas Securities LLC trimmed its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 69.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,899 shares of the company’s stock after selling 15,967 shares during the period. SG Americas Securities LLC’s holdings in Syndax Pharmaceuticals were worth $176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new stake in shares of Syndax Pharmaceuticals in the 1st quarter worth approximately $41,000. Great West Life Assurance Co. Can purchased a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $44,000. Royal Bank of Canada lifted its position in shares of Syndax Pharmaceuticals by 1,144.7% in the 3rd quarter. Royal Bank of Canada now owns 3,622 shares of the company’s stock worth $87,000 after purchasing an additional 3,331 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Syndax Pharmaceuticals by 2,488.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,659 shares of the company’s stock worth $111,000 after purchasing an additional 4,479 shares during the period. Finally, Psagot Value Holdings Ltd. Israel purchased a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth approximately $127,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Syndax Pharmaceuticals

In related news, insider Peter Ordentlich sold 25,000 shares of the firm’s stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $25.84, for a total transaction of $646,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Briggs Morrison sold 52,855 shares of the business’s stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $19.53, for a total transaction of $1,032,258.15. Following the transaction, the director now directly owns 17,836 shares in the company, valued at $348,337.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter Ordentlich sold 25,000 shares of Syndax Pharmaceuticals stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $25.84, for a total transaction of $646,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 183,564 shares of company stock worth $4,000,684. 4.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of Syndax Pharmaceuticals from $41.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, March 7th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, April 14th. The Goldman Sachs Group reduced their price objective on shares of Syndax Pharmaceuticals from $39.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, March 1st. Stifel Nicolaus started coverage on shares of Syndax Pharmaceuticals in a research note on Monday, January 30th. They set a “buy” rating and a $37.00 price objective for the company. Finally, Citigroup reduced their price objective on shares of Syndax Pharmaceuticals from $32.00 to $31.00 in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.86.

Syndax Pharmaceuticals Trading Up 3.1 %

Shares of Syndax Pharmaceuticals stock opened at $21.07 on Friday. Syndax Pharmaceuticals, Inc. has a 12-month low of $13.27 and a 12-month high of $29.86. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -8.60 and a beta of 1.11. The firm’s 50 day simple moving average is $21.24 and its two-hundred day simple moving average is $23.39.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. On average, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.04 EPS for the current fiscal year.

About Syndax Pharmaceuticals

(Get Rating)

Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.